Floatz logo

LEUPROLIDE

ER Positive Breast Cancer

Olema Pharmaceuticals, Inc.protein_peptidePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the ER Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
Palazestrant
Olema Pharmaceuticals, Inc.
Phase 3BB
Vinorelbine
Massachusetts General Hospital
Phase 2BB
Alpelisib
Jennifer Lee Caswell-Jin
Phase 2B
Tucatinib
Dana-Farber Cancer Institute
Phase 2B
Zotatifin
Jennifer Lee Caswell-Jin
Phase 2B

View all 17 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →